[go: up one dir, main page]

CY1115254T1 - Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις - Google Patents

Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις

Info

Publication number
CY1115254T1
CY1115254T1 CY20141100513T CY141100513T CY1115254T1 CY 1115254 T1 CY1115254 T1 CY 1115254T1 CY 20141100513 T CY20141100513 T CY 20141100513T CY 141100513 T CY141100513 T CY 141100513T CY 1115254 T1 CY1115254 T1 CY 1115254T1
Authority
CY
Cyprus
Prior art keywords
preparation
procedures
therapeutic uses
pharmaceutical solutions
pharmaceutical
Prior art date
Application number
CY20141100513T
Other languages
English (en)
Inventor
Eric Schenkel
Claire Poulain
Bertrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115254(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma, S.A. filed Critical Ucb Pharma, S.A.
Publication of CY1115254T1 publication Critical patent/CY1115254T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ένα σταθερό φαρμακευτικό διάλυμα, σε μία διαδικασία για την παρασκευή του και στις θεραπευτικές χρήσεις του.
CY20141100513T 2008-03-03 2014-07-08 Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις CY1115254T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
EP09716304.2A EP2273975B8 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
CY1115254T1 true CY1115254T1 (el) 2017-01-04

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100513T CY1115254T1 (el) 2008-03-03 2014-07-08 Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις

Country Status (21)

Country Link
US (1) US20110021786A1 (el)
EP (1) EP2273975B8 (el)
JP (6) JP2011513360A (el)
KR (1) KR101353425B1 (el)
CN (1) CN101945647B (el)
AU (1) AU2009221177B2 (el)
BR (1) BRPI0908421C1 (el)
CA (1) CA2715685C (el)
CY (1) CY1115254T1 (el)
DK (1) DK2273975T3 (el)
EA (1) EA018736B1 (el)
ES (1) ES2474945T3 (el)
HK (1) HK1148202A1 (el)
HR (1) HRP20140634T1 (el)
IL (1) IL207558A (el)
MX (1) MX2010009222A (el)
PL (1) PL2273975T3 (el)
PT (1) PT2273975E (el)
RS (1) RS53418B (el)
SI (1) SI2273975T1 (el)
WO (1) WO2009109547A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
CA2740610C (en) * 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
ES2588504T3 (es) 2008-10-22 2016-11-03 Array Biopharma, Inc. Compuestos de pirazolo[1,5-a]pirimidina sustituidos como compuestos intermedios en la síntesis de inhibidores de TRK quinasa
DK2358361T3 (en) * 2008-11-18 2016-12-12 Ucb Biopharma Sprl DEPOT formulation comprising a 2-oxo-1-pyrrolidine.
PL2790695T3 (pl) 2011-12-16 2016-07-29 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A Kompozycja farmaceutyczna zawierająca (S)-2-(2-oksopirolidyn-1-ylo)butanamid
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
AU2013249034B2 (en) * 2012-04-19 2016-04-28 C. R. Bard, Inc. Infusates with enhanced pH stability under ethylene oxide sterilization
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
DK3439662T3 (da) 2016-04-04 2024-09-02 Loxo Oncology Inc Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3800189T3 (da) 2016-05-18 2023-07-31 Loxo Oncology Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
EP3951452A4 (en) 2019-03-28 2022-12-28 Toyobo Co., Ltd. ANTI-REFLECTIVE CIRCULAR POLARIZER AND IMAGE DISPLAY USING IT
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法
EP4505994A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution formulation comprising brivaracetam
EP4505995A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution composition comprising brivaracetam
WO2025038056A1 (en) * 2023-08-11 2025-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi An oral solution comprising brivaracetam
EP4505996A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. An oral solution comprising brivaracetam
CN118986873A (zh) * 2024-08-19 2024-11-22 海南卫康制药(潜山)有限公司 一种布立西坦溶液的制备方法及其布立西坦溶液

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1758855B1 (en) * 2004-06-11 2007-11-21 UCB Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
JP2015145382A (ja) 2015-08-13
EA018736B1 (ru) 2013-10-30
DK2273975T3 (da) 2014-06-30
JP2011513360A (ja) 2011-04-28
SI2273975T1 (sl) 2014-09-30
US20110021786A1 (en) 2011-01-27
PT2273975E (pt) 2014-07-17
EP2273975B1 (en) 2014-04-09
KR101353425B1 (ko) 2014-02-18
EA201001402A1 (ru) 2011-06-30
RS53418B (en) 2014-12-31
ES2474945T3 (es) 2014-07-10
CA2715685A1 (en) 2009-09-11
BRPI0908421A2 (pt) 2015-08-04
EP2273975B8 (en) 2014-12-17
AU2009221177B2 (en) 2013-05-30
HRP20140634T1 (hr) 2014-11-21
KR20100126466A (ko) 2010-12-01
CN101945647B (zh) 2013-01-09
JP2017114890A (ja) 2017-06-29
IL207558A0 (en) 2010-12-30
PL2273975T3 (pl) 2014-09-30
JP2019089837A (ja) 2019-06-13
HK1148202A1 (en) 2011-09-02
CN101945647A (zh) 2011-01-12
CA2715685C (en) 2015-04-28
BRPI0908421C1 (pt) 2021-05-25
WO2009109547A1 (en) 2009-09-11
EP2273975A1 (en) 2011-01-19
BRPI0908421B1 (pt) 2020-08-04
JP2022169734A (ja) 2022-11-09
JP2020128384A (ja) 2020-08-27
IL207558A (en) 2015-02-26
MX2010009222A (es) 2010-09-28
AU2009221177A1 (en) 2009-09-11
BRPI0908421B8 (pt) 2020-08-18

Similar Documents

Publication Publication Date Title
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CY1115932T1 (el) Σκευασμα αντισωματος
CY1115030T1 (el) Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
CY1120758T1 (el) Σταθερα στοματικα διαλυματα για συνδυασμενα εφς
CY1120094T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας
LT2451482T (lt) Kombinuota terapija, skirta diabeto gydymui
CY1122711T1 (el) Μεθοδος για την ενεργοποιηση και τη συζευξη βιομοριων
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
EA200970816A1 (ru) Новая лекарственная форма
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом